Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 2/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 10/20 | 0.40 |
| ▸ | HTR1A | P08908 | 8/20 | 0.40 |
| ▸ | HTR2A | P28223 | 8/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.37 |
| ▸ | BRS3 | P32247 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29809401 | 1.00 | PDE3B (0.50) | PDE3BPDE3ADRD2HTR1AHTR2A | |
| SCHEMBL17928610 | 0.89 | MAPT (0.43) | PDE3BPDE3ADRD2HTR1AHTR2A | |
| SCHEMBL12680338 | 0.83 | PDE3B (0.49) | PDE3BPDE3ACYP2C19 | |
| SCHEMBL5366571 | 0.78 | CA9 (0.47) | PDE3BPDE3ADRD2HTR1AHTR2A | |
| SCHEMBL4148301 | 0.78 | PDE3B (0.43) | PDE3BPDE3ADRD2HTR1AHTR2A | |
| SCHEMBL21671865 | 0.78 | PDE3B (0.43) | PDE3BPDE3ADRD2HTR1AHTR2A | |
| SCHEMBL18202413 | 0.78 | PDE3B (0.43) | PDE3BPDE3ADRD2HTR1AHTR2A | |
| SCHEMBL5371747 | 0.78 | PDE3B (0.43) | PDE3BPDE3ADRD2HTR1AHTR2A | |
| SCHEMBL13937428 | 0.77 | PDE3B (0.47) | PDE3BPDE3ADRD2HTR1AHTR2A | |
| SCHEMBL13111251 | 0.77 | PDE3B (0.43) | PDE3BPDE3ADRD2HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-9572801-B2 | Tetrahydronaphthyridinyl propionic acid derivatives and uses thereof | SCIFLUOR LIFE SCIENCES, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20160317527-A1 | TETRAHYDRONAPHTHYRIDINYL PROPIONIC ACID DERIVATIVES AND USES THEREOF | SCIFLUOR LIFE SCIENCES, INC. | 2016-11-03 | — | — | US | disclosed |
| WO-2016176532-A1 | TETRAHYDRONAPHTHYRIDINYL PROPIONIC ACID DERIVATIVES AND USES THEREOF | SCIFLUOR LIFE SCIENCES, INC. (US) | 2016-11-03 | — | — | WO | disclosed |
| US-9156822-B2 | Functionally selective ligands of dopamine D2 receptors | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156822-B2 | Functionally selective ligands of dopamine D2 receptors | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2015-10-13 | — | — | US | disclosed |
| EP-2022793-B1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2014-06-04 | — | — | EP | disclosed |
| US-20130137679-A1 | Novel Functionally Selective Ligands of Dopamine D2 Receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-05-30 | — | — | US | disclosed |
| US-20130137679-A1 | Novel Functionally Selective Ligands of Dopamine D2 Receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-05-30 | — | — | US | disclosed |
| US-8367831-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| US-8211908-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-8211908-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-8211908-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| EP-2022793-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-02-11 | — | — | EP | disclosed |
| US-7235562-B2 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC (US) | 2007-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | PDE3B 4693/4885PDE3A 4572/4885DRD2 4049/4885 |
| US-20130137679-A1 | Novel Functionally Selective Ligands of Dopamine D2 Receptors | DRD2, AVPR2, NTSR2 | PDE3B 892/4885PDE3A 725/4885DRD2 1/4885 |
| US-20160317527-A1 | TETRAHYDRONAPHTHYRIDINYL PROPIONIC ACID DERIVATIVES AND USES THEREOF | CPT1A, CFTR, SLC10A1 | PDE3B 369/4885PDE3A 273/4885DRD2 2091/4885 |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | IKZF3, ZC3HAV1L, H1-4 | PDE3B 4670/4885PDE3A 4706/4885DRD2 666/4885 |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | IKZF3, ZC3HAV1L, CXXC5 | PDE3B 4571/4885PDE3A 4627/4885DRD2 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.